MedTrace Logo

Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

NCT03028311 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-03-10

No results posted yet for this study

Summary

This clinical trial studies the side effects and best way to perform yttrium Y-90 radioembolization in treating patients with liver cancer that has spread to other places in the body (metastatic). Yttrium Y-90 radioembolization is a therapy that injects radioactive microspheres directly into an artery that feeds liver tumors to cut off their blood supply. Performing yttrium Y-90 radioembolization in a single session may make treatment faster, minimize patient travel, and decrease the overall cost of the procedure.

Conditions

  • Metastatic Liver Carcinoma
  • Stage IV Liver Cancer
  • Stage IVA Liver Cancer
  • Stage IVB Liver Cancer

Interventions

PROCEDURE

Angiography

Undergo angiography

PROCEDURE

Computed Tomography

Undergo SPECT-CT

PROCEDURE

Planar Imaging

Undergo planar imaging

RADIATION

Radioembolization

Undergo radioembolization

PROCEDURE

Single Photon Emission Computed Tomography

Undergo SPECT-CT

RADIATION

Technetium Tc-99m Albumin Aggregated

Given via arterial catheter

OTHER

Yttrium Y 90 Resin Microspheres

Given via arterial catheter

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Armeen Mahvash · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-09
Primary Completion
2027-01-31
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03028311 on ClinicalTrials.gov